7.71

2.16% -0.17

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Why RCUS Down? Discussions Forecast

Arcus Biosciences Inc stock is traded at $7.71, with a volume of 1.16M. It is down -2.16% in the last 24 hours and down -13.76% over the past month. Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Previous Close:

$7.88

Open:

$7.71

24h Volume:

1.16M

Relative Volume:

1.12

Market Cap:

$812.86M

Revenue:

$247.00M

Net Income/Loss:

$-249.00M

P/E Ratio:

-2.4951

EPS:

-3.09

Net Cash Flow:

$-267.00M

1W Performance:

+0.39%

1M Performance:

-13.76%

6M Performance:

-54.57%

1Y Performance:

-47.16%

1-Day Range:

$7.65

$8.00

1-Week Range:

$7.555

$8.02

52-Week Range:

$6.50

$18.98

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

(510) 694-6200

Address

3928 POINT EDEN WAY, HAYWARD, CA

Employee

674

Twitter

@arcusbio

Next Earnings Date

2024-12-06

Latest SEC Filings

RCUS's Discussions on Twitter

Compare RCUS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCUS Arcus Biosciences Inc	7.71	812.86M	247.00M	-249.00M	-267.00M	-3.09
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-21-24	Initiated	H.C. Wainwright	Neutral
Oct-08-24	Initiated	Wells Fargo	Overweight
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

Apr 20, 2025

Geode Capital Management LLC Decreases Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World

Apr 20, 2025

Apr 19, 2025

Certain restricted stock units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Certain Options of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Alliancebernstein L.P. - Defense World

Apr 19, 2025

Apr 11, 2025

Vanguard Group Inc. Sells 79,539 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World

Apr 11, 2025

Apr 10, 2025

Corebridge Financial Inc. Sells 2,258 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World

Apr 10, 2025

American Century Companies Inc. Increases Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World

Apr 10, 2025

Apr 09, 2025

Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus

Apr 09, 2025

Arcus Biosciences Announces New Employment Inducement Grants - Bluefield Daily Telegraph

Apr 09, 2025

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Apr 09, 2025

Apr 08, 2025

Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies - Investing.com Australia

Apr 08, 2025

Arcus Biosciences’ SWOT analysis: biotech stock’s potential in cancer therapies By Investing.com - Investing.com South Africa

Apr 08, 2025

Arcus Biosciences' SWOT analysis: biotech stock's potential in cancer therapies - Investing.com

Apr 08, 2025

Raymond James Financial Inc. Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World

Apr 08, 2025

Apr 03, 2025

RCUS stock touches 52-week low at $7.5 amid market challenges - Investing.com

Apr 03, 2025

RCUS stock touches 52-week low at $7.5 amid market challenges By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 02, 2025

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha

Apr 02, 2025

(RCUS) Trading Signals - news.stocktradersdaily.com

Apr 02, 2025

Apr 01, 2025

Institutional owners may consider drastic measures as Arcus Biosciences, Inc.'s (NYSE:RCUS) recent US$134m drop adds to long-term losses - simplywall.st

Apr 01, 2025

Mar 29, 2025

Arcus Biosciences, Inc.'s (NYSE:RCUS) latest 8.6% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo

Mar 29, 2025

Mar 25, 2025

RCUS stock touches 52-week low at $8.81 amid market challenges - Investing.com

Mar 25, 2025

Mar 17, 2025

RCUS stock touches 52-week low at $8.97 amid market challenges - Investing.com Australia

Mar 17, 2025

RCUS stock touches 52-week low at $8.97 amid market challenges By Investing.com - Investing.com South Africa

Mar 17, 2025

Mar 14, 2025